Proteomic-based biomarkers are now an integral part of the drug development process. This chapter covers the role of proteomic biomarker tests as useful tools for improving preclinical research and clinical development. One medical area that has been lagging behind this process is the study of psychiatric disorders, and this is most likely due to the complexity of these diseases. The potential of incorporating biomarkers in the clinical pipeline to improve decision-making, accelerate drug development, improve translation and reduce development costs is also discussed, with a focus on psychiatric diseases like schizophrenia. This chapter will also discuss the next steps that must be taken to keep moving this process forwards.
CITATION STYLE
Rahmoune, H., Martins-de-Souza, D., & Guest, P. C. (2017). Application of proteomic approaches to accelerate drug development for psychiatric disorders. In Advances in Experimental Medicine and Biology (Vol. 974, pp. 69–84). Springer New York LLC. https://doi.org/10.1007/978-3-319-52479-5_4
Mendeley helps you to discover research relevant for your work.